papillary cystadenocarcinoma


Summary: An adenocarcinoma in which the tumor elements are arranged as finger-like processes or as a solid spherical nodule projecting from an epithelial surface.

Top Publications

  1. Kobayashi I, Kiyoshima T, Ozeki S, Shima K, Shigemura N, Matsuo K, et al. Immunohistochemical and ultrastructural study of a papillary cystadenocarcinoma arising from the sublingual gland. J Oral Pathol Med. 1999;28:282-6 pubmed
    Immunohistochemical and ultrastructural findings in a rare case of papillary cystadenocarcinoma arising from the left sublingual gland of a 55-year-old Japanese man are reported...
  2. Arai Y, Kusakabe H, Kiyokane K. A case of syringocystadenocarcinoma papilliferum in situ occurring partially in syringocystadenoma papilliferum. J Dermatol. 2003;30:146-50 pubmed
  3. Hemminki K, Granström C. Familial invasive and borderline ovarian tumors by proband status, age and histology. Int J Cancer. 2003;105:701-5 pubmed
    ..Histopathology and age of onset appear to be important attributes of familial ovarian cancer, suggesting that further gene identification efforts should target a specific histopathology in early-onset patients...
  4. Slomovitz B, Burke T, Eifel P, Ramondetta L, Silva E, Jhingran A, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91:463-9 pubmed
    ..The identified characteristics were then correlated with overall survival (OS)...
  5. Naoe M, Ogawa Y, Fuji K, Fukagai T, Inoue K, Yoshida H. Papillary cystadenocarcinoma of the prostate. Int J Urol. 2004;11:1036-8 pubmed
    ..Immunohistochemically, the tumor originated from the prostate...
  6. Xing J, Dang J, Wu D, Long Q, Chen X, Nan X. [Papillary cystadenocarcinoma in a Müllerian duct cyst: report of a case with literature review]. Zhonghua Nan Ke Xue. 2006;12:218-21 pubmed
    ..To study the diagnosis and treatment of Müllerian duct cysts and their involvement with malignancy...
  7. Harimaya A, Somekawa Y, Sasaki M, Ohuchi T. Cystadenocarcinoma (papillary cystadenocarcinoma) of the submandibular gland. J Laryngol Otol. 2006;120:1077-80 pubmed
    Cystadenocarcinoma (papillary cystadenocarcinoma) of the salivary gland is a rare malignant neoplasm...
  8. Kimura Y, Ariyoshi Y, Miyatake S, Shimahara M, Kawabata S, Ono K. Boron neutron capture therapy for papillary cystadenocarcinoma in the upper lip: a case report. Int J Oral Maxillofac Surg. 2009;38:293-5 pubmed publisher
    ..The authors report their first experience of BNCT on a patient with no history of surgery, chemotherapy or conventional radiotherapy for papillary cystadenocarcinoma in the upper lip.
  9. Berker B, Ortac F, Ataoglu O. Axillary lymphadenopathy as the primary presentation of primary peritoneal carcinoma. Gynecol Obstet Invest. 2002;54:232-6 pubmed
    ..In the case of an isolated axillary adenocarcinoma various kinds of immunohistochemical tests should be performed in order to elucidate the origin of the malignancy. ..

More Information

Publications108 found, 100 shown here

  1. Santin A, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002;8:1271-9 pubmed
  2. DuBeshter B, Deuel C, Gillis S, Glantz C, Angel C, Guzick D. Endometrial cancer: the potential role of cervical cytology in current surgical staging. Obstet Gynecol. 2003;101:445-50 pubmed
    ..Further study of those with normal cervical cytology is needed to determine if lymphadenectomy can be omitted with grade 1 tumor on biopsy, or whether aortic lymphadenectomy is necessary regardless of grade. ..
  3. Kim H, Kim J, Cho K. CT features of serous surface papillary carcinoma of the ovary. AJR Am J Roentgenol. 2004;183:1721-4 pubmed
    ..Serous surface papillary carcinoma of the ovary should be suggested as a diagnosis in patients who have peritoneal carcinomatosis, relatively normal-sized ovaries, and a highly elevated serum CA-125 level. ..
  4. Ng J, Han A, Edelson M, Rosenblum N. Uterine papillary serous carcinoma presenting as distant lymph node metastasis. Gynecol Oncol. 2001;80:417-20 pubmed
    ..This tumor should be considered in the differential diagnosis when patients present with metastatic high-grade papillary serous carcinomas and the primary site is unknown. ..
  5. Singer G, Kurman R, Chang H, Cho S, Shih I. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002;160:1223-8 pubmed
    ..The other pathway is characterized by rapid progression from the ovarian surface epithelium or inclusion cysts to a conventional (high-grade) serous carcinoma...
  6. Reed J, Hakam A, Nicosia S, Coppola D. Significance of Fas receptor protein expression in epithelial ovarian cancer. Hum Pathol. 2005;36:971-6 pubmed
  7. Komiyama S, Asai S, Dokoh J, Tsuji H, Ishikawa M, Mikami M. Papillary serous carcinoma of the peritoneum with paraaortic lymph node metastasis despite minimal intraperitoneal involvement: a case report. Acta Cytol. 2006;50:323-6 pubmed
    ..PSCP can present with an early paraaortic lymph node metastasis. Endometrial cytology can be valuable in the diagnosis. ..
  8. Goldberg H, Miller R, Abdah Bortnyak R, Steiner M, Yildiz F, Meirovitz A, et al. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol. 2008;108:298-305 pubmed
    ..Conservative surgery followed by adjuvant chemotherapy and pelvic radiotherapy can be suggested as an appropriate treatment approach for patients treated with curative intent. ..
  9. Piura B, Meirovitz M, Cohen Y, Horowitz J. Dermatomyositis and peritoneal papillary serous carcinoma. Eur J Obstet Gynecol Reprod Biol. 1999;82:93-6 pubmed
    ..This case illustrates that, alongside the more frequently occurring ovarian carcinoma, PPSC should also be considered in the differential diagnosis of the underlying malignancy that may occur in the female patient with DM. ..
  10. Prat J, De Nictolis M. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol. 2002;26:1111-28 pubmed
    ..The micropapillary pattern alone does not imply an unfavorable prognosis; only micropapillary tumors associated with invasive implants behave aggressively. ..
  11. Bozkurt N, Yuce K, Basaran M, Kose F, Ayhan A. Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer. Obstet Gynecol. 2004;103:82-5 pubmed
    ..72 +/- 0.08 (P =.026). In patients with progressive disease and positive second-look laparotomy, preoperative platelet counts were significantly higher compared with patients with no evidence of disease on follow-up. ..
  12. Ahluwalia A, Hurteau J, Bigsby R, Nephew K. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol. 2001;82:299-304 pubmed
  13. Eltabbakh G, Mount S, Beatty B, Simmons Arnold L, Cooper K. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma. J Surg Oncol. 2006;93:379-86 pubmed
    ..Although further studies with larger number of patients are needed, our findings indicate that chemoresistance in CCOC is probably not p53-dependent. ..
  14. Lindahl B, Persson J, Ranstam J, Willen R. Long-term survival in uterine clear cell carcinoma and uterine papillary serous carcinoma. Anticancer Res. 2010;30:3727-30 pubmed
    ..In stage Ia, 2/46 patients died of their disease and amongst all the stages, 30/109 patients died of their disease. These survival outcomes are comparable to or better than those presented previously. ..
  15. Patterson J, Straka B, Wick M. Linear syringocystadenoma papilliferum of the thigh. J Am Acad Dermatol. 2001;45:139-41 pubmed
    ..Linear lesions occurring in other locations are rare. We report such a case occurring on the thigh, documented by multiple biopsy specimens. The case is discussed in the context of other adnexal tumors that may form linear arrangements...
  16. Debnath K, Singh A, Singh Y, Devi P, Devi S. Plasma cell leukaemia with papillary serous cystadenocarcinoma of ovary--a case report. Indian J Pathol Microbiol. 2003;46:446-7 pubmed
    ..A rare case of plasma cell leukaemia and papillary serous cystadenacarcinoma of ovary in a 58-year-old female is reported. ..
  17. Amin M. Selected other problematic testicular and paratesticular lesions: rete testis neoplasms and pseudotumors, mesothelial lesions and secondary tumors. Mod Pathol. 2005;18 Suppl 2:S131-45 pubmed
  18. Santin A, Zhan F, Cane S, Bellone S, Palmieri M, Thomas M, et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer. 2005;92:1561-73 pubmed
    ..Our results highlight the novel molecular features of USPC and provide a foundation for the development of new type-specific therapies against this highly aggressive variant of endometrial cancer. ..
  19. Lavie O, Hornreich G, Ben Arie A, Renbaum P, Levy Lahad E, Beller U. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol. 2000;96:28-32 pubmed
  20. Shappell H, Riopel M, Smith Sehdev A, Ronnett B, Kurman R. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002;26:1529-41 pubmed
    ..We therefore recommend the term "seromucinous" for these tumors, which acknowledges both their serous and mucinous features. ..
  21. Pérez Guillermo M, Solano J. Fine-needle aspiration of apocrine hidrocystoma--a potential mimic of papillary neoplasms metastasizing to the skin. Diagn Cytopathol. 2004;30:275-9 pubmed
  22. Nagar Y, Singh S, Sawlani V, Pal L, Dimri K, Lal P. Primary papillary serous cystadenocarcinoma of broad ligament. Australas Radiol. 2005;49:160-2 pubmed
    ..This patient showed a complete response to adjuvant cisplatin-based chemotherapy following panhysterectomy and is presently without any evidence of disease, 15 months after completion of her treatment. ..
  23. Walker A, Mills S. Serous and mesothelial proliferations of the extraovarian peritoneum and pelvic lymph nodes. Pathology (Phila). 1993;1:411-39 pubmed
    ..Discussion of each type focuses on clinical and morphologic features, histogenesis, differential diagnosis, and clinical outcome...
  24. Gao J, Zheng A, Chen W, Peng Z, Cao Z. [A study of prognostic factors of stage IV epithelial ovarian cancer]. Hua Xi Yi Ke Da Xue Xue Bao. 2001;32:309-12 pubmed
    ..25 times, 11.44 times and 1.85 times respectively (P < 0.05). Surgical debulking, aggressive and appropriate chemotherapy are important measures to improve survival rate for patients with stage IV epithelial ovarian cancer. ..
  25. Chambers J, Rutherford T, Schwartz P, Carcangiu M, Chambers S, Baker L. A pilot study of topotecan in the treatment of serous carcinoma of the uterus. Int J Gynecol Cancer. 2003;13:216-22 pubmed
    ..Further evaluation of topotecan in this population is warranted. ..
  26. Park S, Shin Y, Shin D, Choi J, Kim K. Syringocystadenocarcinoma papilliferum: a case report. J Korean Med Sci. 2007;22:762-5 pubmed
    ..We established the diagnosis of SCACP in the patient, and a wide excision was performed to remove the tumor. The patient has been well without relapse or metastasis for 2 yr...
  27. Kayikcioglu F, Boran N, Ayhan A, Guler N. Inflammatory breast metastases of ovarian cancer: a case report. Gynecol Oncol. 2001;83:613-6 pubmed
    ..The finding of isolated, distant metastases such as breast involvement without intraabdominal disease is extremely rare. Determining the origin of the primary tumor is important in directing the actual therapy. ..
  28. Nishio S, Kawata T, Harada C, Kawagoe H, Fujiyoshi K, Ishimatsu J, et al. [A case of extraovarian primary peritoneal carcinoma successfully treated with weekly paclitaxel]. Gan To Kagaku Ryoho. 2002;29:309-12 pubmed
    ..Weekly 1-hour paclitaxel (70 mg/m2) was well tolerated, yet was effective for extraovarian primary peritoneal carcinoma. ..
  29. Lammens L, Fenton D. Abnormal glandular smear: first evidence of ovarian malignancy. J Obstet Gynaecol. 2002;22:702 pubmed
  30. Hashimoto H, Kojima A, Sudo T, Ohki N, Yamaguchi S, Mikami Y, et al. Establishment and characterization of a human cell line derived from a uterine papillary serous carcinoma with wild-type p53 function. Hum Cell. 2008;21:64-9 pubmed publisher
    ..This newly established cell line should be useful for investigating the characteristics of uterine papillary serous carcinoma. ..
  31. Colgan T, Murphy J, Cole D, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001;25:1283-9 pubmed
    ..The entire ovaries and tubes from PO patients should be submitted for histologic examination to identify malignancy...
  32. Altaras M, Bernheim J, Zehavi T, Drucker L, Uziel O, Fishman A. Papillary serous carcinoma of the peritoneum coexisting with or after endometrial carcinoma. Gynecol Oncol. 2002;84:245-51 pubmed
  33. Slomovitz B, Broaddus R, Burke T, Sneige N, Soliman P, Wu W, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004;22:3126-32 pubmed
    ..Overexpression of Her-2/neu was associated with a worse overall prognosis. The use of trastuzumab (Herceptin; Genentech, South San Francisco, CA) in women with UPSC should be further evaluated in a clinical trial setting. ..
  34. Khan N, Maajeeni E. Tubo-ovarian abscess in a postmenopausal woman with underlying ovarian carcinoma. Saudi Med J. 2005;26:1010-1 pubmed
  35. Batchelor E, Watkins J, Creasman W, Kohler M, Sinha D, Jenrette J. The role of radiotherapy in the management of resected uterine papillary serous and clear cell carcinoma. Eur J Obstet Gynecol Reprod Biol. 2008;141:163-8 pubmed publisher
    ..Hysterectomy with adjuvant radiotherapy significantly improves disease-free survival within 2 years post-hysterectomy and significantly reduces loco-regional failures over hysterectomy alone. ..
  36. Lavie O, Ben Arie A, Pilip A, Rennert G, Cohen Y, Feiner B, et al. BRCA2 germline mutation in a woman with uterine serous papillary carcinoma--case report. Gynecol Oncol. 2005;99:486-8 pubmed
    ..A strong family history of breast and ovarian cancer with the presence of the BRCA2 germline mutation is an additional hint for the possible association between BRCA cancer predisposing mutations and USPC. ..
  37. Hosokawa C, Tsubakimoto M, Inoue Y, Nakamura T. Bilateral primary fallopian tube carcinoma: findings on sequential MRI. AJR Am J Roentgenol. 2006;186:1046-50 pubmed
  38. Rao P, Shenoy K, Rai S. Plasma cell leukemia with ovarian serous cystadenocarcinoma. Indian J Pathol Microbiol. 2007;50:663 pubmed
  39. Bel L, Tecilla M, Borza G, Peştean C, Purdoiu R, Ober C, et al. Diagnosis and surgical management of malignant ovarian teratoma in a green iguana (Iguana iguana). BMC Vet Res. 2016;12:144 pubmed publisher
    ..and for green iguanas previously reported cases include teratomas, one adenocarcinoma and one papillary cystadenocarcinoma. The present report is the first of a malignant ovarian teratoma in a green iguana...
  40. Iyengar T, Herzog T. Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter. Am J Hosp Palliat Care. 2002;19:35-8 pubmed
    ..The Pleurx' catheter offers a number of potential advantages over traditional treatment modalities. Clearly, larger study numbers are required to quantify the morbidity associated with the Pleurx catheter. ..
  41. Miller J, Geisler J, Manahan K, Geisler H, Miller G, Zhou Z, et al. Nuclear size, shape, and density in endometrial carcinoma: relationship to survival at over 5 years of follow-up. Does analyzing only cells occupying the G0-G1 peak add useful information?. Int J Gynecol Cancer. 2004;14:138-44 pubmed
    ..Measuring nuclear morphometric features in the G0-G1 peak only does not add any new prognostic information. ..
  42. Dunham C, Curry B, Hamilton M. Malignant transformation of an intraaxial-supratentorial neurenteric cyst - case report and review of the literature. Clin Neuropathol. 2009;28:460-6 pubmed consistent with a neurenteric cyst exhibiting malignant transformation into an invasive mucinous papillary cystadenocarcinoma. Areas of direct transition between typical benign neurenteric cyst epithelia and malignant epithelia (..
  43. Lee S. [Clinical approach to incidental pancreatic cystic lesions]. Korean J Gastroenterol. 2010;55:154-61 pubmed
    ..Therefore, evidence-based guidelines for the diagnosis, management, and follow-up of cystic lesions of the pancreas should be established. ..
  44. Thomas M, Mariani A, Cliby W, Keeney G, Podratz K, Dowdy S. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol Oncol. 2007;107:190-3 pubmed
    ..Uterine papillary serous carcinoma (UPSC) frequently presents in advanced stages. The aim of this study was to assess the role of cytoreduction in stage IIIC-IV UPSC...
  45. Cohen M, Shawis R, Evans C. Paratesticular müllerian-type papillary serous tumor in a child. Pediatr Dev Pathol. 2009;12:297-300 pubmed publisher
    ..The pediatric surgeon, the clinicians, and the pathologist should be aware of this entity, as a conservative management would be preferable. ..
  46. Staebler A, Heselmeyer Haddad K, Bell K, Riopel M, Perlman E, Ried T, et al. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Hum Pathol. 2002;33:47-59 pubmed
    ..Other cases of MPSC with independent genetic alterations may represent another subset of tumors that are a distinct entity from APST and SC...
  47. Goldstein N, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol. 2002;117:541-5 pubmed
    ..The mechanisms underlying these findings are unknown. They raise the possibility of genetic differences between the 2 morphologically similar neoplasms...
  48. Jain V, Bali H, Kalra J, Gopalan S, Bhargava M, Saha S. Preoperative vena caval interruption for venous thrombosis associated with ovarian malignancy. Acta Obstet Gynecol Scand. 2002;81:270-1 pubmed
  49. Slomovitz B, Lu K. Commenting on "HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? (88:263-5) by Santin AD". Gynecol Oncol. 2004;92:386-7; author reply 387 pubmed
  50. Kanayama S, Yamada Y, Haruta S, Naruse K, Furukawa N, Kawaguchi R, et al. Peritoneal disseminated recurrence and lung metastasis after surgery for stage IA uterine papillary serous carcinoma of the endometrium: a case report. Arch Gynecol Obstet. 2008;278:277-80 pubmed publisher
    ..We describe a case of synchronous peritoneal dissemination and multiple lung metastases after surgery for stage IA primary uterine papillary serous carcinoma (UPSC) of the endometrium, revealed by an uncontrollable retention of ascites...
  51. Gupta D, Merino M, Farhood A, Middleton L. Metastases to breast simulating ductal carcinoma in situ: report of two cases and review of the literature. Ann Diagn Pathol. 2001;5:15-20 pubmed
    ..When there is any unusual histomorphology, a good degree of suspicion is necessary. Ann Diagn Pathol 5:15-20, 2001...
  52. Griffiths C, Parker L, Lee S, Finkler N. The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term results. Int J Gynecol Cancer. 2002;12:323-31 pubmed
    ..Cytoreduction is not always required but even large-volume disease in the upper abdomen can be safely excised. The concept that masses larger than 10 cm indicate general chemoresistance has not been sustained...
  53. Halperin R, Zehavi S, Langer R, Hadas E, Bukovsky I, Schneider D. Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study. Eur J Gynaecol Oncol. 2002;23:300-4 pubmed
  54. Urmancheeva A, Ul rikh E, Neustadt E, Zel dovich D, Dikareva A. [Serous-papillary endometrial carcinoma (clinico-morphological features)]. Vopr Onkol. 2002;48:679-83 pubmed
    ..05). High incidence of association of metastasis and superficial or deep invasion was reported for SPEC. This tumor should be classified as pathogenetic variant II of clinico-morphological changes...
  55. Wu W, Slomovitz B, Celestino J, Chung L, Thornton A, Lu K. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas. Cancer Res. 2003;63:6195-9 pubmed
    ..However, in UPSC/CCC, cdc25B is highly expressed without coordinate increase in phosphorylated ER-alpha. Cdc25B may play important roles in the development and progression of EEC and UPSC/CCC by different mechanisms...
  56. Kebapci M, Yalcin O, Dundar E, Ozalp S, Kaya T. Computed tomography findings of primary serous papillary carcinoma of the peritoneum in women. Eur J Gynaecol Oncol. 2003;24:552-6 pubmed
  57. Schnee D. The adnexal mass in pregnancy. Mo Med. 2004;101:42-5 pubmed
    ..Adnexal masses occur in approximately one in 600 pregnancies, of which the risk of malignancy is up to 5%. The decision to proceed with conservative versus operative intervention is discussed in this article...
  58. Cronk M, Abraham R, Perrin L. Case report of a generalized seizure related to Paclitaxel infusion. J Natl Cancer Inst. 2004;96:487 pubmed
  59. Santin A, Diamandis E, Bellone S, Soosaipillai A, Cane S, Palmieri M, et al. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Clin Cancer Res. 2005;11:3320-5 pubmed
    ..The discovery of novel biomarkers might greatly contribute to improve clinical management and outcomes in uterine serous papillary carcinoma (USPC), a highly aggressive variant of endometrial cancer...
  60. Kajbafzadeh A, Djaladat H. Extraprostatic papillary cystadenocarcinoma of the prostate. South Med J. 2006;99:1285-6 pubmed
    ..On pathology, papillary cystadenocarcinoma with positive immunohistochemical staining for PSA was confirmed.
  61. Grunstein E, Kacker A. Salivary gland cystadenocarcinoma of the mobile tongue, low-grade papillary adenocarcinoma variant: a case report. Ear Nose Throat J. 2006;85:829-30 pubmed
    ..Treatment involves local excision; neck dissection and postoperative radiation therapy are used for clinically positive neck metastases. The prognosis varies according to the clinical stage and grade of the tumor...
  62. Tsujimoto Y, Satoh M, Takada T, Honda M, Matsumiya K, Fujioka H, et al. Papillary cystadenocarcinoma of the prostate: a case report. Hinyokika Kiyo. 2007;53:67-70 pubmed
    ..was performed to relieve the main symptoms and the resected material was histologically diagnosed as papillary cystadenocarcinoma arising from the epithelium of microscopic retention cysts...
  63. Santin A, Bellone S, Marizzoni M, Palmieri M, Siegel E, McKenney J, et al. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). Cancer. 2007;109:1312-22 pubmed
    ..The potential for targeting this pathway in the treatment of USPC was explored...
  64. Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, et al. Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol. 2008;108:221-9 pubmed
  65. Konecny G, Agarwal R, Keeney G, Winterhoff B, Jones M, Mariani A, et al. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. Gynecol Oncol. 2008;109:263-9 pubmed publisher
    ..Our aim was to determine the expression pattern and prognostic relevance of claudin-3 and claudin-4 in a large cohort of endometrial cancer patients of diverse histological type and stage...
  66. Inoue S, Kagawa M, Watanabe Y, Kusanishi H. [A case of ovarian cancer in which a remarkable effect was seen with low-dose CDDP intratumoral injection of CPT-11]. Gan To Kagaku Ryoho. 2002;29:2336-8 pubmed
    ..CPT-11 (40 mg/day) was administered twice a week. As a result, marked shrinkage of the tumors was confirmed. This low-dose CDDP intratumoral injection with CPT-11 may be effective for such omental tumors with carcinomatous peritonitis...
  67. Matulonis U, Campos S, Duska L, Fuller A, Berkowitz R, Gore S, et al. A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecol Oncol. 2003;91:293-8 pubmed
    ..The primary endpoints were surgically defined response rates and evaluation of toxicity...
  68. Baykal C, Demirtas E, Al A, Yuce K, Tulunay G, Kose M, et al. Comparison of HGF (hepatocyte growth factor) levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts. Int J Gynecol Cancer. 2003;13:771-5 pubmed
    ..Mechanisms that take a role in HGF secretion and the responses of neighboring epithelial cells to HGF during tumoral development need to be investigated...
  69. Trieu L, Thambugala G, Loh Y. Intraductal papillary mucinous tumour of the pancreas: imaging features. Australas Radiol. 2004;48:230-2 pubmed
    ..The imaging characteristics of a case in an 82-year-old woman are compared...
  70. Lee C, Slomovitz B, Greer M, Sharma S, Gregurich M, Burke T, et al. Practice patterns of SGO members for stage IIIA endometrial cancer. Gynecol Oncol. 2005;98:77-83 pubmed
    ..The aim of this study was to survey the Society of Gynecologic Oncologists (SGO) members and fellows about their approach to the treatment of patients with stage IIIA endometrial cancer...
  71. Tong G, Chiriboga L, Hamele Bena D, Borczuk A. Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?. Mod Pathol. 2007;20:856-63 pubmed
  72. Deligdisch L, Penault Llorca F, Schlosshauer P, Altchek A, Peiretti M, Nezhat F. Stage I ovarian carcinoma: different clinical pathologic patterns. Fertil Steril. 2007;88:906-10 pubmed
    ..To analyze clinicopathologic patterns of early ovarian carcinoma...
  73. Lee A, Paish E, Marchio C, Sapino A, Schmitt F, Ellis I, et al. The expression of Wilms' tumour-1 and Ca125 in invasive micropapillary carcinoma of the breast. Histopathology. 2007;51:824-8 pubmed
    ..One previous study found Ca125 expression in 69% of invasive micropapillary carcinomas. The aim was to assess the frequency of expression of WT1 and Ca125 in invasive micropapillary carcinoma...
  74. Pantanowitz L, Otis C, Goulart R. Cytologic findings of psammocarcinoma in peritoneal washings. Acta Cytol. 2009;53:263-7 pubmed
  75. Dharan M. Utility of cell block preparation in endometrial aspiration cytology: a report of 4 cases. Acta Cytol. 2010;54:893-7 pubmed
    ..Endometrial aspiration (EA) cytology is a simple yet highly useful diagnostic procedure for uterine and extrauterine malignancies...
  76. Thai T, Du F, Tsan J, Jin Y, Phung A, Spillman M, et al. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum Mol Genet. 1998;7:195-202 pubmed
    ..These findings suggest an occasional role for BARD1 mutations in the development of sporadic and hereditary tumors...
  77. Zheng W, Khurana R, Farahmand S, Wang Y, Zhang Z, Felix J. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol. 1998;22:1463-73 pubmed
    ..Therefore, the term uterine surface carcinoma is selected to alert clinicians that this early carcinoma has features of carcinoma in situ, but still carries a potential for metastasis...
  78. Rosique C, Winant C, Deviere J, Matos C. Intraductal papillary mucinous tumor of the pancreas demonstrated by MR cholangiopancreatography. JBR-BTR. 2002;85:44 pubmed
  79. Agarwal N, Parul -, Kriplani A, Bhatla N, Gupta A. Management and outcome of pregnancies complicated with adnexal masses. Arch Gynecol Obstet. 2003;267:148-52 pubmed
    ..Ultrasound was unable to distinguish malignant cases. Pregnancy outcome was poorer if surgical intervention was done after >24 weeks and that, too, was done as emergency surgery...
  80. Usatoff V, Wittkop B, Devalia K, Guest P, Buckels J. Solid papillary-cystic carcinoma of the pancreas with portal vein tumour thrombus. ANZ J Surg. 2004;74:291-3 pubmed
  81. Varras M, Akrivis C, Bellou A, Malamou Mitsi V, Antoniou N, Tolis C, et al. Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up. Eur J Gynaecol Oncol. 2004;25:640-6 pubmed
    ..At 60 months after initial surgery, the patient is alive and well. In conclusion, our study suggests an association between fallopian tube carcinoma and breast cancer and a good response of the patient to platinum-based chemotherapy...
  82. Thyagarajan M, Abdi S. Recurrent ovarian carcinoma presenting as a solitary metastasis to the kidney. Br J Radiol. 2008;81:e293-4 pubmed publisher
    ..Unusual sites for recurrent ovarian metastases include extrahepatic solid organs (except the spleen), bone and the abdominal wall. We report a rare renal recurrence of ovarian malignancy and its imaging features...
  83. Manini C, Pietribiasi F, Sapino A, Donadio S. [Serous cystadenocarcinoma of the ovary with simultaneous breast metastases. Description of a case]. Pathologica. 1998;90:152-5 pubmed
    ..On the basis of clinical, morphological and immunohistochemical data we proposed the diagnosis of papillary cystoadenocarcinoma of the ovary with simultaneous metastasis to the breast and axillary lymph nodes...
  84. Mesia A, Tarafder D, Shanerman A, Cohen J. Peritoneal cytology in uterine papillary serous carcinoma. Acta Cytol. 1999;43:605-9 pubmed
    ..To highlight the significance of positive peritoneal cytology in uterine papillary serous carcinoma (UPSC)...
  85. Hasenburg A, Fischer D, Tong X, Rojas Martinez A, Nyberg Hoffman C, Orlowska Volk M, et al. Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer. Int J Gynecol Cancer. 2002;12:66-73 pubmed
    ..ADV-HSV-tk GT appears to eliminate cells with higher differentiation first and might induce fibrosis. Dedifferentiation might render residual cells more sensitive to chemotherapy secondary to their subsequent higher mitotic activity...
  86. Carlson N, Krivak T, Winter W, Macri C. Port site metastasis of ovarian carcinoma remote from laparoscopic surgery for benign disease. Gynecol Oncol. 2002;85:529-31 pubmed
    ..However, as we continue to realize the benefits and expand the scope of laparoscopic procedures, new complications may occur...
  87. Memarzadeh S, Holschneider C, Bristow R, Jones N, Fu Y, Karlan B, et al. FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int J Gynecol Cancer. 2002;12:454-8 pubmed
    ..We conclude that primary surgical cytoreduction resulting in microscopic residual disease is associated with an improvement in recurrence-free survival and overall survival in women with UPSC...
  88. Ali S, Saeed O, Muzaffar S, Riaz T, Setna F, Ayub S. Fallopian tube carcinoma presenting as cervical growth: the dilemma of skip metastasis. Aust N Z J Obstet Gynaecol. 2003;43:82-4 pubmed
  89. Pitkin R. Julian CG, Woodruff JD. The biologic behavior of low-grade papillary serous carcinoma of the ovary. Obstet Gynecol 1972; 40:860-7. Obstet Gynecol. 2003;102:452 pubmed
  90. Sakorafas G, Sarr M. Cystic neoplasms of the pancreas; what a clinician should know. Cancer Treat Rev. 2005;31:507-35 pubmed
    ..In the absence of invasive disease, prognosis is excellent after appropriate surgery. The presence of invasive malignancy signifies a poor prognosis...
  91. Dehari R, Kurman R, Logani S, Shih I. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol. 2007;31:1007-12 pubmed
    ..The above results suggest that the majority of high-grade and low-grade carcinomas develop independently but in rare cases, a high-grade serous carcinoma may arise from an atypical proliferative serous (borderline) tumor...
  92. Granström C, Sundquist J, Hemminki K. Population attributable fractions for ovarian cancer in Swedish women by morphological type. Br J Cancer. 2008;98:199-205 pubmed
    ..The risks for women with a family history were among the highest, but these women accounted for the smallest proportion of the cases, giving the lowest PAFs...